Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR(R)

PITTSBURGH, Nov. 17 Mylan Inc. (NYSE: MYL) todayannounced that its subsidiary, Mylan Pharmaceuticals Inc., received tentativeapproval from the U.S. Food and Drug Administration (FDA) for its AbbreviatedNew Drug Application (ANDA) for Venlafaxine Hydrochloride (HCl)Extended-release (ER) Capsules, 37.5 mg (base), 75 mg (base) and 150 mg(base).

Venlafaxine HCl ER Capsules, indicated for the treatment of majordepressive disorder and generalized anxiety disorder, are the generic versionof Wyeth Pharmaceutical Inc.'s Effexor XR(R) Capsules. This product had annualU.S. sales of approximately $3 billion for the 12 months ending Sept. 30,2008, for the noted strengths, according to IMS Health.

Currently, Mylan has 112 ANDAs pending FDA approval, 23 of which arepotential first-to-file opportunities.

Mylan Inc., which provides products to customers in more than 140countries and territories, ranks among the leading diversified generic andspecialty pharmaceutical companies in the world. The company maintains one ofthe industry's broadest -- and highest quality -- product portfolios,supported by a robust product pipeline; owns a controlling interest in theworld's third largest active pharmaceutical ingredient manufacturer; andoperates a specialty business focused on respiratory and allergy therapies.For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...